← SynDRA
ELAFIBRANOR
SynDRA canonical compound SYN0038520 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | PPARA | PPARD | PPARG |
|---|
| Mechanism of action | PPAR receptor agonist |
|---|
All known targets
Mechanisms of action (all sources)
- PPARA AGONIST
- Peroxisome proliferator-activated receptor alpha agonist
- PPARD AGONIST
- Peroxisome proliferator-activated receptor delta agonist
- PPAR receptor agonist
- PPARD MODULATOR
- PPARA MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABL1
- AURKA
- TRIM24
- TDG
- SMUG1
- RXRA
- OGG1
- NTHL1
- NR5A1
- NR4A1
- NR2E1
- NR2C1
- NEIL2
- NEIL1
- MUTYH
- MPG
- MBD4
- MAPK1
- LTB4R2
- HNF4A
- HDAC6
- GSK3B
- FGFR3
- CSNK1D
- CDK2
- BRPF1
- BRD4
- UNG
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
ATC classes
Cross-references
Synonyms
- IQIRVO
- Iqirvo
- GFT505
- GFT-505
- GFT-1007
- PPAR activator (dyslipidemia/type 2 diabetes), Genfit
- 2J3H5C81A5
- GFT 505
- elafibranorum
- RefChem:590672
- DTXCID601527265
- Elafibranor(GFT505)
- Elafibranor [INN]
- Elafibranor [USAN]
- (E/Z)-Elafibranor
- MFCD27987940
- Elafibranor (USAN)
- C22H24O4S
- UNII-2J3H5C81A5
- Iqirvo (TN)
- GFT-505;Elafibranor
- Elafibranor(GFT505)?
- ELAFIBRANOR [WHO-DD]
- SCHEMBL815512
- orb1302884
- GTPL11135
- EX-A757
- ZHB93288
- BDBM50502541
- HY-16737A
- s3720
- AKOS027325486
- CCG-268462
- CS-5522
- NCGC00510491-02
- AC-31455
- AC-35189
- AS-57112
- BE163306
Look up ELAFIBRANOR in the interactive SynDRA portal →